Lupin Q4 Results Preview: Net profit likely to more than double, margin may expand by 700 bps

Lupin Q4 FY24 Results Preview: Mumbai-headquartered pharmaceutical company Lupin is all set to report its financial results for the January-March period on May 6. Analysts expect the drug maker to stage a strong performance for the three-month period on the back of product launches, and robust revenue growth in the US and European markets. 

According to Zee Business research, Lupin is estimated to register a net profit of Rs 559 crore for the quarter ended March 31, more than double over a net profit of Rs 236 crore for the corresponding period a year ago. The analysts expect the pharma company's quarterly revenue to grow 16.4 per cent to Rs 5,156 crore.

Lupin is expected to log earnings before interest, taxes, depreciation and amortisation (EBITDA) of Rs 1,022 crore for the March quarter, up 77 per cent on a year-on-year basis, according to the research. 

Zee Business analysts peg the drug maker's margin, a key measure of profitability, at 20 per cent for the fiscal fourth quarter, as against 13 per cent a year ago. They expect the company's revenue from its key US and European markets to increase 35 per cent and 21 per cent on a year-on-year basis, respectively. 

The analysts estimate the drug manufacturer to clock revenue growth to the tune of 10 per cent in its domestic business.

Lupin shares: Past performance

The Lupin stock has grown almost 28 per cent so far this year, sharply outperforming a 3.2 per cent rise in the headline Nifty50 index and a 14 per cent jump in the Nifty Pharma gauge. 

Lupin shares have rewarded investors with a 129 per cent return in a year, while the Nifty and Nifty Pharma indices have gained 23 per cent and 52 per cent, respectively.

Catch all the latest stock market updates here. For all other news related to business, politics, tech and auto, visit Zeebiz.com.